AVNS AVANOS MEDICAL, INC. revenue, earnings and financials

For the quarter ended March 31, 2026, AVANOS MEDICAL, INC. reported revenue of $182M (up 8.8% from a year earlier), net income of $5.10M and diluted EPS of $0.11; over the last four quarters revenue was $716M and net income −$74.4M; for the fiscal year ended December 2025 revenue was $701M, up 1.9% on the year before.

AVNS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $701M, gross profit $354M, operating income −$61.6M, net income −$72.9M (margin -10.4%), EPS −$1.57
• Fiscal year ended Dec 2024: revenue $688M, gross profit $381M, operating income −$396M, net income −$392M (margin -57.0%), EPS −$8.53
• Fiscal year ended Dec 2023: revenue $673M, gross profit $380M, operating income $4.20M, net income −$61.8M (margin -9.2%), EPS −$1.32
• Fiscal year ended Dec 2022: revenue $684M, gross profit $394M, operating income $35.5M, net income $50.5M (margin 7.4%), EPS $1.07
• Fiscal year ended Dec 2021: revenue $587M, gross profit $299M, operating income −$39.0M, net income $6.30M (margin 1.1%), EPS $0.13

AVNS quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $182M (up 8.8% year over year), net income $5.10M, EPS $0.11
• Quarter ended Dec 31, 2025 (from the annual report): revenue $181M (up 0.7% year over year), net income −$1.30M, EPS −$0.02
• Quarter ended Sep 30, 2025: revenue $178M (up 4.3% year over year), net income −$1.40M, EPS −$0.03
• Quarter ended Jun 30, 2025: revenue $175M (up 1.9% year over year), net income −$76.8M, EPS −$1.66
• Quarter ended Mar 31, 2025: revenue $168M (up 0.8% year over year), net income $6.60M, EPS $0.14
• Quarter ended Dec 31, 2024 (from the annual report): revenue $180M (up 3.6% year over year), net income −$397M, EPS −$8.64
• Quarter ended Sep 30, 2024: revenue $170M (down 0.5% year over year), net income $4.30M, EPS $0.09
• Quarter ended Jun 30, 2024: revenue $172M (up 1.4% year over year), net income $1.80M, EPS $0.04
• Quarter ended Mar 31, 2024: revenue $166M (up 4.3% year over year), net income −$900K, EPS −$0.02
• Quarter ended Dec 31, 2023 (from the annual report): revenue $173M (up 20.8% year over year), net income $10.5M, EPS $0.23
• Quarter ended Sep 30, 2023: revenue $171M (down 0.6% year over year), net income −$3.70M, EPS −$0.08
• Quarter ended Jun 30, 2023: revenue $169M (down 0.9% year over year), net income −$68.1M, EPS −$1.46
• Quarter ended Mar 31, 2023: revenue $159M (down 19.3% year over year), net income −$500K, EPS −$0.01
• Quarter ended Dec 31, 2022 (from the annual report): revenue $144M (up 300.8% year over year), net income $16.9M, EPS $0.37
• Quarter ended Sep 30, 2022: revenue $172M (down 6.4% year over year), net income $15.7M, EPS $0.33
• Quarter ended Jun 30, 2022: revenue $171M (down 8.3% year over year), net income $12.5M, EPS $0.26
• Quarter ended Mar 31, 2022: revenue $197M (up 9.2% year over year), net income $5.40M, EPS $0.11
• Quarter ended Dec 31, 2021 (from the annual report): revenue $35.8M, net income $11.5M, EPS $0.24
• Quarter ended Sep 30, 2021: revenue $184M, net income −$35.3M, EPS −$0.73
• Quarter ended Jun 30, 2021: revenue $186M, net income $38.5M, EPS $0.79

AVNS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $74.7M, share buybacks $3.30M
• Fiscal year ended Dec 2024: operating cash flow $101M, share buybacks $12.8M
• Fiscal year ended Dec 2023: operating cash flow $32.4M, share buybacks $19.1M
• Fiscal year ended Dec 2022: operating cash flow $90.9M, share buybacks $45.5M
• Fiscal year ended Dec 2021: operating cash flow $87.3M, share buybacks $11.5M

AVNS balance sheet

• Mar 31, 2026: cash $65.6M, total assets $1.05B, total liabilities $268M, shareholders' equity $782M
• Dec 31, 2025: cash $89.8M, total assets $1.07B, total liabilities $296M, shareholders' equity $778M
• Sep 30, 2025: cash $70.5M, total assets $1.07B, total liabilities $290M, shareholders' equity $778M
• Jun 30, 2025: cash $90.3M, total assets $1.04B, total liabilities $263M, shareholders' equity $776M
• Mar 31, 2025: cash $97.0M, total assets $1.11B, total liabilities $268M, shareholders' equity $839M
• Dec 31, 2024: cash $108M, total assets $1.15B, total liabilities $326M, shareholders' equity $829M
• Sep 30, 2024: cash $89.0M, total assets $1.66B, total liabilities $427M, shareholders' equity $1.23B
• Jun 30, 2024: cash $92.2M, total assets $1.66B, total liabilities $436M, shareholders' equity $1.22B

What is AVNS's revenue?

AVANOS MEDICAL, INC. reported $716M of revenue over its last four quarters, through March 31, 2026.

Is AVNS profitable?

No. AVANOS MEDICAL, INC. lost $74.4M over the last four quarters.

What is AVNS's EPS?

Diluted earnings per share over the last four quarters were −$1.60; $0.11 in the latest quarter.

AVNS ownership and insider trades · All stocks